[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554049":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":25,"responsibleParty":43,"collaborators":46,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"University of Miami","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Prophylaxis guided by Cytomegalovirus-specific T cell Immunity",null,"The immunological response of participants in this group will be followed for 1 year.",[13],{"name":14,"affiliation":5,"role":15},"Yoichiro Natori, MD","PRINCIPAL_INVESTIGATOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","3053556323","yxn138@med.miami.edu",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Lissett Moni","3053555418","ltueros@med.miami.edu",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Miami","Florida","33136","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-80.19366,25.77427,{"lat":37,"lon":36},[40,41,42],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},{"name":14,"role":15,"phone":10,"phoneExt":10,"email":10},{"type":15,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Yoichiro Natori","Associate Professor of Clinical",[47],{"name":48,"class":49},"Eurofins Viracor","UNKNOWN","100554049","prophylaxis-guided-by-cytomegalovirus-specific-t-cell-immunity-to-prevent-cytomegalovirus-disease-in-lung-transplant-recipients-100554049",false,"NCT06494033","Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients","Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients: a Single Center Prospective Study","Inclusion Criteria:\n\n1. Adult patients over 18 years of age\n2. Lung transplant candidates with positive CMV IgG\n3. Anticipated to receive a lung transplant (both double lung and single lung)\n\nExclusion Criteria:\n\n1. Negative CMV IgG prior transplant\n2. Pregnant or breastfeeding women\n3. HIV infected patients\n4. Combined organ (e.g., lung-heart, lung-kidney) transplant candidates","ALL","18 Years","75 Years",{"count":61,"type":62},100,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.",[66],"Lung Diseases","2026-03-18",{"date":69,"type":70},"2026-03-23","ACTUAL",{"date":72,"type":70},"2024-07-03",{"date":74,"type":62},"2026-12-30",{"name":5,"class":6},1]